Executive Summary : | Endometrial cancer, particularly carcinoma endometrium, is a prevalent gynecological malignancy worldwide, affecting a large number of women annually. Despite advancements in diagnosis and treatment, there is still a need for a better understanding of its underlying mechanisms, accurate diagnostic tools, and effective therapeutic strategies. The study of molecular and pathological characteristics of carcinoma endometrium and their correlation with patient outcomes holds great promise for addressing these gaps and improving clinical management. Introduction of the molecular profile of carcinoma endometrium, including genetic alterations and gene expression patterns, is crucial for understanding the underlying mechanisms involved in the development and progression of the disease. This knowledge can facilitate the development of novel treatments, such as targeted therapies or immunotherapies, that specifically address the aberrant molecular alterations driving endometrial cancer. Examination of histopathological features of carcinoma endometrium can significantly impact early detection, accurate diagnosis, and prognostic assessment of the disease. This can help tailor treatment strategies, select appropriate surgical approaches, and predict patient outcomes more accurately. Correlating molecular and pathological characteristics with patient outcomes, including overall survival, disease-free survival, and recurrence rates, is vital for identifying predictive biomarkers. The discovery of biomarkers associated with treatment response and patient prognosis can guide personalized treatment decisions, leading to improved survival rates and quality of life. |